rEECur: An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Sarcoma: Ewing sarcoma
This trial aims to discover which is the most successful treatment for a child or young person who has relapsed with Ewing Sarcoma. Currently, it is not known which chemotherapy drug combination provides the most successful treatment for a child or young person who has relapsed. This trial, the first of its kind world-wide, aims to find out which course of treatment is the most effective and with the least side effects.
The trial allows for four different chemotherapy drug combinations to be randomly given to each child or young person. These drug combinations are called ‘treatment arms’. There are some exclusions based on a number of factors including what treatment the child or young person has already received. To be included the child or young person needs to be eligible for at least 2 treatment arms.
Disease Stage: Recurrent or primary refractory
Patient Age Range: >4 years to <50 years
Sample Size: 600
- International: University of Birmingham
- National: ANZCHOG in partnership with ANZSA